Treatment with177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with90Y-DOTATOC

Journal of Nuclear Medicine

Volumn 46, Issue 8, 2005, Pages 1310-1316

  Forrer, Flavio ^a   Uusijärvi, Helena ^b   Storch, Daniel ^a   Maecke, Helmut R ^a   Mueller Brand, Jan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

177Lu DOTATOC; 90Y DOTATOC; Neuroendocrine tumors; Radionuclide therapy; Somatostatin

Indexed keywords

ANALGESIC AGENT; DOMPERIDONE; OCTREOTIDE; ONDANSETRON; RADIOISOTOPE; TETRAAZACYCLODODECANE TETRAACETYL DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLTHREONYLCYSTEINYLTHREONINOL LU 177; TETRAAZACYCLODODECANE TETRAACETYL DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLTHREONYLCYSTEINYLTHREONINOL Y 90; UNCLASSIFIED DRUG; 177LU OCTREOTIDE, DOTA(0) TYR(3); 177LU-OCTREOTIDE, DOTA(0)-TYR(3)-; 90Y OCTREOTIDE, DOTA TYR(3); 90Y-OCTREOTIDE, DOTA-TYR(3)-; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL TUMOR; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG TOLERABILITY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; LONG TERM CARE; MALE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PAIN; PRIORITY JOURNAL; RECURRENT DISEASE; WHOLE BODY SCINTISCANNING; CARCINOMA; FEASIBILITY STUDY; FOLLOW UP; METASTASIS; MIDDLE AGED; SCINTISCANNING; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; CARCINOMA, NEUROENDOCRINE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OCTREOTIDE; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 25444469094     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Faiss S, Pape UF, Bohmig M, et al. International lanreotide and interferon alfa study group: prospective, randomized, multicenter trial on the antiproliferative effect of lanreutide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors. J Clin Oncol. 2003;21:2689-2696.
2. Kaltsas GA, Mukherjee JJ, Isidori A, et al. Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil. Clin Endocrinol (Oxf). 2002;57:169-183.
3. Moertel CG, Kvols LK, G'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68:227-232.
4. Dharmsathaphorn K, Sherwin RS, Cataland S, et al. Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med. 1980;92:68-69.
5. Vinik A, Moattari AR. Use of somatostatin analog in management of carcinoid syndrome. Dig Dis Sci. 1989;34(suppl 3):14S-27S.
6. Anthony LB, Martin W, Delbeke D, et al. Somatostatin receptor imaging: predictive and prognostic considerations. Digestion 1996;57(suppl 1):50-53.
7. 90Y-DOTATOC. J Nucl Med. 2002;43:610-616.
8. 3-octreotide in therapy of neuroendocrine malignancies. Biopolymers. 2002;66:393-398.
9. Otte A, Herrmann R, Heppeler A, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999;26:1439-1447.
10. 90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941-945.
11. 3]octreotate. Eur J Nucl Med. 2003;30:417-422.
12. Anthony LE, Woltering EA, Espanan GD, et al. Indium-333-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002;32123-132.
13. 0] octreotide: the Rotterdam experience. Semin Nucl Med. 2002;32:110-122.
14. 3]octreotate. J Clin Oncol. 2004;22:2724-2729.
15. Krenning EP, Kwekkeboom DJ, Valkema, et al. Peptide receptor radionuclide therapy. Ann N Y Acad Sci. 2004;1014:234-245.
16. Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy: Yttrium-90-DOTATOC internal radiotherapy. Am J Kidney Dis. 2001;37:847-851.
17. 3]-octreotide in patients with somatostatin receptor positive tumours [abstract]. Eur J Nucl Med Mol. Imaging 2003;30(suppl 2):S232.
18. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med. 2005;46(suppl 1):62S-66S.
19. 3-octreotate in patients with neuroendocrine tumors: interim results [abstract]. Eur J Nucl Med Mol Imaging. 2003;30(suppl 2):S231.
20. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med. 1998;25:201-212.
21. 177Lu. J Nucl Med. 2004;45:1260-1269.
22. Reubi J, Schaer J, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes. SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeuuc use. Eur J Nucl Med. 2000;27:273-282.
23. 111In-DOTATATE biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1257-1262.
24. Wild D, Schmitt JS, Ginj M, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338-1347.
25. Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9-15.
26. 3-octreotide (SMT487): a phase 1 clinical study-pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging. 2003;30:510-518.
27. RADAR medical procedure radiation dose calculator and consent language generator. Stanford Dosimetry, LLC, Web site. Available at: http://www. doseinfo-radar.com/RADARDoseRiskCalc.html. Accessed June 6, 2005.
28. 90Y-DOTATOC. Eur J Nucl Med. 1999;26:877-886.
29. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1386-1392.
30. Forrer F, Mueller-Brand J, Maecke H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2005;32:511-512.
31. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109-122.
32. Bernhardt P, Forssell-Aronsson E, Jacobsson L, et al. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol. 2001;40:602-608.
33. 3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628-633.
34. 90Y: peptide receptor radionuclide therapy results in vitro. Cancer Biother Radiopharm. 2003;18:761-768.
35. Joiner MC, Marples B, Lambin P, et al. Low-dose hypersensitivity: current status and possible mechanisms. Int J Radiat Oncol Biol Phys. 2001;49:379-389.